IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
A Penn syl va nia court is su ing 13 ma jor phar ma ceu ti cal com pa nies, in clud ing TAP, ac cus ing them of in -
flat ing prices in an al leged scheme that cost the gov ern ment, in sur ers, and con sum ers hun dreds of mil -
lions of dol lars. If the law suit suc ceeds, con sum ers who pur chased ar ti fi cially over priced drugs would be
eligible for rebates.
Takeda busi ness of fice man ag ers will per son ally take on the ed u ca tion/train ing re spon si bil ity. The nearly
270 team lead ers were as signed ei ther man ag ers of the nearly 70 new of fices or “ex pert MRs” (about
170) who dem on strate ex em plary de tail ing ac tiv i ties to the other MRs. Takeda plans to hire 240 new MR
can di dates in the year to March 31 2005. Takeda an nounced the es tab lish ment of Takeda Global Re -
search and De vel op ment Cen ter (TGRD) in Il li nois, USA. The new or ga ni za tion, to be lo cated on TPNA’s
cam pus in Lincolshire, Il li nois, will in te grate the clin i cal de vel op ment ac tiv ity of TPNA’s R&D group and
Takeda’s Eu ro pean R&D cen ter. This will in volve the trans fer of TPNA’s ex ist ing R&D to the new cen ter.
The Takeda’s Eu rope R&D Cen ter will re port to TGRD. The new or ga ni za tion will be headed by Dr John
Yates, former VP for Medical and Scientific Affairs at Merck & Co (USA).
• Year: 2003
A US Dis trict Court judge ruled that lit i ga tion aris ing from al leged im proper pric ing of Lupron (leuprorelin)
by Takeda, TAP and Abbott, could pro ceed. The lit i ga tion claims that il le gal mar ket ing and sales prac tices
re sulted in ex ces sive costs be ing paid by consumers.
Takeda an nounced a re or ga ni za tion of its do mes tic pro duc tion sys tem, in volv ing clo sure of its plant in
Fujisawa by March 2006 and re struc tur ing its ac tiv i ties at Hikari. Pro duc tion of con sumer healthcare
prod ucts will move to Fukuchiyama, and eth i cal man u fac ture will move to Hikari, where Takeda plans to
in vest Yen15 bil lion. This will be come Takeda’s main pro duc tion fa cil ity and will in clude pro duc tion of spe -
cific raw ma te ri als, for mu la tion of vac cines and microcapsule for mu la tion of Leuplin (leuprorelin).
Takeda’s Osaka plant is to con tinue its spe cial ist production and research until further notice.
Takeda’s wholly owned US hold ing com pany, Takeda Amer i can Hold ings, re ceived a cash in jec tion of
$2.6 bil lion from the par ent com pany in mid 2003. The hold ing com pany over sees both Takeda
Pharmaceuticals north Amer ica TPNA and TAP, and the move will help to fund fur ther busi ness ex pan sion
in the USA.
Chugai (Ja pan) an nounced plans to sell the Takeda Re search Lab o ra tory site to Kajima (Ja pan).
Takeda bought back 3% of its stock in an ef fort to bol ster its sag ging share price. The firm will buy up to
30 mil lion of its own shares (Yen140 bil lion).
The Aus tra lian Com pe ti tion and Con sumer Com mis sion filed a com plaint against Roche, BASF, and
Takeda, al leg ing they par tic i pated in fix ing the price of vi ta min C. The com pa nies were part of a vi ta mins
car tel which ended in 1999 and took part in fix ing global prices of vi ta min C between 1991 and 1995.
Takeda signed a con sult ing agree ment with BioConsul Drug De vel op ment (USA). BCDD will ad vise on
tech ni cal and fi nan cial as pects of li cens ing agree ments with US bio tech nol ogy and biopharmaceutical
companies.
• Year: 2002
Sumitomo Chem i cal (Ja pan) and Takeda con cluded a jv and trans fer-of-busi ness agree ment ini ti ated in
July 2002. The two com pa nies have es tab lished the jv Sumitomo Chem i cal Takeda Agro Com pany, which
took over Takeda’s do mes tic agro chemi cal busi ness at the be gin ning of No vem ber 2002. Sumitomo will
con trol 60% of the com pany, and Takeda 40%. Af ter five years, the To kyo-based jv (named Sumika)
may be in te grated into Sumitomo’s agro chemi cals busi ness. The jv has a cap i tal of Yen9,380 mil lion and
© 2009 IMS Health In cor po rated or its af fil i ates Page 114